Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
| ▸ | POLD1 | P28340 | 1/20 | 0.65 |
| ▸ | TK1 | P04183 | 7/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265387 | 0.98 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL3031874 | 0.98 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL30586988 | 0.98 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL77582 | 0.98 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL18855348 | 0.98 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL28961478 | 0.96 | POLB (0.61) | POLBPOLA1POLD1TK1ALB | |
| Triphosphate SCHEMBL27892350 | 0.95 | POLB (0.61) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL23440065 | 0.91 | TK1 (0.67) | POLBPOLA1POLD1TK1 | |
| SCHEMBL28774920 | 0.91 | TK1 (0.67) | POLBPOLA1POLD1TK1 | |
| SCHEMBL8883 | 0.91 | TK1 (0.67) | POLBPOLA1POLD1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| US-12145951-B2 | Inorganic-organic hybrid compounds including organic platinum-containing anions, for use in medicine | KARLSRUHER INSTITUT FUR TECHNOLOGIE (DE) | 2024-11-19 | — | — | US | claimed |
| CN-117265046-A | Application of rhamnosyl transferase in rhamnosylation modification of natural product | 山东大学 | 2023-12-22 | — | — | CN | claimed |
| CN-114903028-B | Erythrocyte cryoprotectant and preparation method and application thereof | 华南理工大学 | 2023-10-17 | — | — | CN | claimed |
| US-20230174991-A1 | KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS | INBIOSE N.V. (BE) | 2023-06-08 | — | — | US | claimed |
| CN-114903028-A | Erythrocyte cryoprotectant and preparation method and application thereof | 华南理工大学 | 2022-08-16 | — | — | CN | claimed |
| US-20210292353-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-09-23 | — | — | US | claimed |
| EP-3829565-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2021-06-09 | — | — | EP | claimed |
| WO-2020025488-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2020-02-06 | — | — | WO | claimed |
| CN-106660944-A | Hybrid inorganic-organic compounds | 卡尔斯鲁尔工学院 | 2017-05-10 | — | — | CN | claimed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | claimed |
| WO-2016168735-A1 | NUCLEOSIDE SUPPLEMENTATION TO PROMOTE CELLULAR FUNCTION, GENETIC STABILITY AND AUGMENT TRANSGENIC EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-20 | — | — | WO | claimed |
| EP-3058061-A1 | NUCLEOSIDE SUPPLEMENTATION TO PROMOTE CELLULAR FUNCTION, GENETIC STABILITY AND REGENERATIVE APPLICATIONS | The Regents of the University of California (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015057997-A1 | NUCLEOSIDE SUPPLEMENTATION TO PROMOTE CELLULAR FUNCTION, GENETIC STABILITY AND REGENERATIVE APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-04-23 | — | — | WO | claimed |
| US-8956833-B2 | Methods for control of flux in metabolic pathways through enzyme relocation | GREENLIGHT BIOSCIENCES, INC. (US) | 2015-02-17 | — | — | US | claimed |
| CN-101705269-A | Method for synthesizing deoxythymidine triphosphate through biotechnology | JIANGSU HUARONG BIOLOG TECHNOL | 2010-05-12 | — | — | CN | claimed |
| US-6379898-B2 | BY DEPOLYMERIZING DNA AT A TERMINAL NUCLEOTIDE ENZYMATIC CLEAVAGE WITH A PYROPHOSPHATE MOLECULE TO FORM A FREE DEOXYRIBONUCLEOSIDE TRIPHOSPHATE, AND REACTING WITH ADENOSINE 5'-DIPHOSPHATE TO FORM ATP WITH NUCLEOSIDE DIPHOSPHATE KINASE | SHULTZ JOHN W (US) | 2002-04-30 | — | — | US | claimed |
| EP-0579806-B1 | MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF FOLATE METABOLISM DISORDERS | KRAGLER PETER (DE) | 1999-07-07 | — | — | EP | claimed |
| EP-4749287-A2 | METHOD | Oxford University Innovation Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-1991006671-A1 | MEANS FOR DETECTING HIGHLY PROLIFERATIVE CELLS | INSTITUT PASTEUR (FR) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | POLB 3337/4885POLA1 2702/4885POLD1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.